Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor vs Aspirin After Transcatheter Aortic Valve Implantation
NCT05283356Phase 4
Key facts
- Status
- Recruiting
- Start
- Jan 2022
- Primary completion
- Jun 2027
- Countries
- 1
- Sponsor
- Fundación Biomédica Galicia Sur
- Modality
- Small Molecules
- Drugs
- ticagrelor
- Conditions
- aortic valve stenosis
01
Overview
Phase 4, randomised trial of ticagrelor in aortic valve stenosis (2 arms), sponsored by Fundación Biomédica Galicia Sur. Primary endpoint: Net Adverse Clinical Events at 12 months. Started Jan 2022; status: recruiting.
02
Design
2 arms- Study design
- Randomized
Aspirin 100mg/day
Acetylsalicylic acid 100mg/day after TAVI
Ticagrelor 60mg BID
Ticagrelor 60 mg twice per day after TAVI
03
Who it enrols
Adults with severe symptomatic aortic stenosis accepted for TAVI, with at least one comorbidity (diabetes, CAD, or PAD). Excludes patients requiring chronic oral anticoagulation, with recent ischemic stroke, severe hepatic insufficiency, or active bleeding.
04
Endpoints
Primary
Net Adverse Clinical Events
Secondary
Subclinical valve thrombosis
Major bleeding
Patient-oriented composite endpoints
Beyond the preview
Go deeper on NCT05283356.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05283356.